Advertisement
J. Lipid Res.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1194/jlr.M800553-JLR200 on December 22, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
M800553-JLR200v1
50/5/938    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tancevski, I.
Right arrow Articles by Ritsch, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tancevski, I.
Right arrow Articles by Ritsch, A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Journal of Lipid Research, Vol. 50, 938-944, May 2009
Copyright © 2009 by American Society for Biochemistry and Molecular Biology

The thyromimetic T-0681 protects from atherosclerosis

Ivan Tancevski1,*, Andreas Wehinger{dagger}, Egon Demetz*, Julia Hoefer*, Philipp Eller*, Eva Huber*, Ursula Stanzl*, Kristina Duwensee*, Kristina Auer*, Wilfried Schgoer*, Volker Kuhn§, Catherine Fievet**, Frans Stellaard{dagger}{dagger}, Mats Rudling§§, Bernhard Foeger{dagger}, Josef R. Patsch* and Andreas Ritsch*

* Department of Internal Medicine, Innsbruck Medical University, Innsbruck, Austria
§ Department of Surgery, Innsbruck Medical University, Innsbruck, Austria
{dagger} Department of Internal Medicine, Landeskrankenhaus Bregenz, Bregenz, Austria
** Département d'Athérosclérose, Institut Pasteur de Lille, Lille Cedex, France
{dagger}{dagger} Laboratory of Pediatrics, Center for Liver, Digestive, and Metabolic Diseases, University Medical Center Groningen, Groningen, The Netherlands
§§ Department for Endocrinology, Metabolism, and Diabetes, Molecular Nutrition Unit, and Departments of Medicine and Biosciences and Nutrition, Karolinska Institutet, Karolinska University Hospital Huddinge, S-141 86 Stockholm, Sweden

This work was supported by the Hans and Blanca Moser Stiftung (No. 61-1994/95 to I.T.), by the Medizinische Forschungsfoerderung Innsbruck (No. 4316 to I.T.), by the Jubiläumsfond der Oesterreichischen Nationalbank (No. 12156 to I.T. and A.R.), and by the Fonds zur Foerderung der wissenschaftlichen Forschung (P19999-B05 to A.R.).

Published, JLR Papers in Press, December 22, 2008.

1 To whom correspondence should be addressed. e-mail: ivan.tancevski{at}i-med.ac.at

This report describes studies in hyperlipidemic New Zealand White (NZW) rabbits investigating the impact of the liver-selective thyromimetic T-0681 on lipoprotein metabolism and the development of atherosclerosis. Prolonged treatment with T-0681 increased the hepatic expression of both LDL receptor and scavenger receptor class B, type I without affecting cholesteryl ester transfer protein activity. Upregulation of hepatic lipoprotein receptors was accompanied by a marked decrease of apolipoprotein B-containing lipoproteins, reflected by a 60% reduction of plasma cholesterol and a >70% reduction of plasma triglyceride levels. Most importantly, T-0681 reduced the development of atherosclerosis by 80% in NZW rabbits on high-cholesterol chow. Our data suggest that liver-selective thyromimetics, such as T-0681, may prove to be useful therapeutic agents against the development of atherosclerosis in humans.

Supplementary key words liver-selective thyromimetic • low density lipoprotein receptor • scavenger receptor class B, type I • potential side effects

Abbreviations: ABCA1, adenosine 5'-triphosphate-binding cassette transporter 1; AcLDL, acetylated low density lipoprotein; ALT, alanine-aminotransferase; apoB, apolipoprotein B; AST, aspartate-aminotransferase; CETP, cholesteryl ester transfer protein; CYP7A1, cholesterol 7 {alpha}-hydroxylase; FPLC, fast-protein liquid chromatography; HMG-CoA, 3-hydroxy-3-methylglutaryl-CoA; LDL-C, low density lipoprotein cholesterol; LDLr, low density lipoprotein receptor; NZW, New Zealand White; RCT, reverse cholesterol transport; SR-BI, scavenger receptor class B, type I; T3, 3,3',5'-triiodo-L-thyronine; T4, 3,5,3',5'-tetraiodothyronine; TH, thyroid hormone; VLDL-C, very low density lipoprotein cholesterol


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2009 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement